![Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 ... Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 ...](https://www.thelancet.com/cms/asset/a8001e13-49e3-44c0-b050-179d0a0a5858/gr1.jpg)
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 ...
STECF 13-07 - DCF NPs guidelines plus MS reports.pdf - Data Collection Framework - European Commission
![Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial | Nature Medicine Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-023-02347-y/MediaObjects/41591_2023_2347_Fig1_HTML.png)
Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial | Nature Medicine
![A RANDOMIZED TRIAL COMPARING RIBAVIRIN DOSE REDUCTION VERSUS ERYTHROPOIETIN FOR ANEMIA MANAGEMENT IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC HEPATITIS C RECEIVING BOCEPREVIR PLUS PEGINTERFERON/RIBAVIRIN A RANDOMIZED TRIAL COMPARING RIBAVIRIN DOSE REDUCTION VERSUS ERYTHROPOIETIN FOR ANEMIA MANAGEMENT IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC HEPATITIS C RECEIVING BOCEPREVIR PLUS PEGINTERFERON/RIBAVIRIN](https://www.natap.org/2012/images/042312/042312-2/EASL1.gif)
A RANDOMIZED TRIAL COMPARING RIBAVIRIN DOSE REDUCTION VERSUS ERYTHROPOIETIN FOR ANEMIA MANAGEMENT IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC HEPATITIS C RECEIVING BOCEPREVIR PLUS PEGINTERFERON/RIBAVIRIN
Mectronic Medicale - 𝐴𝑛 ℎ𝑖𝑔ℎ-𝑡𝑒𝑐ℎ 𝑑𝑒𝑣𝑖𝑐𝑒, 𝑑𝑒𝑠𝑖𝑔𝑛𝑒𝑑 𝑡𝑜 𝑜𝑓𝑓𝑒𝑟 𝑡ℎ𝑒 𝑡ℎ𝑒𝑟𝑎𝑝𝑖𝑠𝑡 𝑎𝑙𝑙 𝑡ℎ𝑒 𝑡𝑜𝑜𝑙𝑠 𝑓𝑜𝑟 𝑎 𝑓𝑙𝑒𝑥𝑖𝑏𝑙𝑒 𝑎𝑛𝑑 𝑒𝑓𝑓𝑒𝑐𝑡𝑖𝑣𝑒 𝑡ℎ𝑒𝑟𝑎𝑝𝑦: 𝗶𝗟𝘂𝘅 𝗣𝗟𝗨𝗦! Designed and built entirely ...
![Genomic epidemiology of SARS-CoV-2 reveals multiple lineages and early spread of SARS-CoV-2 infections in Lombardy, Italy | Nature Communications Genomic epidemiology of SARS-CoV-2 reveals multiple lineages and early spread of SARS-CoV-2 infections in Lombardy, Italy | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-020-20688-x/MediaObjects/41467_2020_20688_Fig1_HTML.png)
Genomic epidemiology of SARS-CoV-2 reveals multiple lineages and early spread of SARS-CoV-2 infections in Lombardy, Italy | Nature Communications
![Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study - The Lancet Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study - The Lancet](https://www.thelancet.com/cms/asset/aee99cbc-80a0-49e4-9ac3-6cc4f16265f9/gr1.jpg)
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study - The Lancet
![Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial - The Lancet Oncology Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/asset/209b827d-c7bc-4235-8c71-c999e28e9c68/gr1.jpg)
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial - The Lancet Oncology
![Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial | Nature Medicine Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-023-02321-8/MediaObjects/41591_2023_2321_Fig1_HTML.png)